Shemesh CS - Search Results

1

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.

Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Shemesh CS, et al. Pharmacol Res Perspect. 2020 Dec;8(6):e00685. doi: 10.1002/prp2.685. Pharmacol Res Perspect. 2020. PMID: 33241650 Free PMC article. Clinical Trial.

2

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F, Garg A, Winter H, Ruppel J, Wang X, Bruno R, Jin J, Girish S. Shemesh CS, et al. J Immunother Cancer. 2019 Nov 21;7(1):314. doi: 10.1186/s40425-019-0791-x. J Immunother Cancer. 2019. PMID: 31753029 Free PMC article. Clinical Trial.

3

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.

Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T. Geoerger B, et al. Among authors: shemesh cs. Lancet Oncol. 2020 Jan;21(1):134-144. doi: 10.1016/S1470-2045(19)30693-X. Epub 2019 Nov 25. Lancet Oncol. 2020. PMID: 31780255 Clinical Trial.

4

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Shemesh CS, Chan P, Shao H, Xu DZ, Combs D, Vadhavkar S, Bruno R, Wu B. Shemesh CS, et al. Liver Cancer. 2021 Jun 10;10(5):485-499. doi: 10.1159/000515817. eCollection 2021 Sep. Liver Cancer. 2021. PMID: 34721510 Free PMC article.

5

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.

Huang W, Stader F, Chan P, Shemesh CS, Chen Y, Gill KL, Jones HM, Li L, Rossato G, Wu B, Jin JY, Chanu P. Huang W, et al. Among authors: shemesh cs. Front Pharmacol. 2022 Sep 26;13:974423. doi: 10.3389/fphar.2022.974423. eCollection 2022. Front Pharmacol. 2022. PMID: 36225583 Free PMC article.

6

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.

Shemesh CS, Chan P, Marchand M, Gonçalves A, Vadhavkar S, Wu B, Li C, Jin JY, Hack SP, Bruno R. Shemesh CS, et al. Clin Pharmacol Ther. 2023 Sep;114(3):644-651. doi: 10.1002/cpt.2953. Epub 2023 Jun 2. Clin Pharmacol Ther. 2023. PMID: 37212707 Clinical Trial.

7

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.

Shemesh CS, Agarwal P, Lu T, Lee C, Dere RC, Li X, Li C, Jin JY, Girish S, Miles D, Lu D. Shemesh CS, et al. Cancer Chemother Pharmacol. 2020 May;85(5):831-842. doi: 10.1007/s00280-020-04054-8. Epub 2020 Mar 28. Cancer Chemother Pharmacol. 2020. PMID: 32222808 Free PMC article. Clinical Trial.

8

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S, Wu B. Shemesh CS, et al. Mol Ther. 2021 Feb 3;29(2):555-570. doi: 10.1016/j.ymthe.2020.09.038. Epub 2020 Sep 30. Mol Ther. 2021. PMID: 33038322 Free PMC article. Review.

9

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

Lu D, Lu T, Shi R, Gibiansky L, Agarwal P, Shemesh CS, Dere RC, Ogbu U, Hirata J, Chanu P, Girish S, Jin JY, Li C, Miles D. Lu D, et al. Among authors: shemesh cs. Pharm Res. 2020 Dec 1;37(12):252. doi: 10.1007/s11095-020-02933-6. Pharm Res. 2020. PMID: 33258982 Free PMC article.

10

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).

Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Drakaki A, et al. Among authors: shemesh cs. Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. Clin Cancer Res. 2023. PMID: 37651261 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters